x
Filter:
Filters applied
- Genomics and Proteomics
- MSRemove MS filter
- May - November 2022Remove May - November 2022 filter
Genomics and Proteomics
2 Results
- Research ArticleOpen Access
Src-mediated phosphorylation of the ribosome biogenesis factor hYVH1 affects its localization, promoting partitioning to the 60S ribosomal subunit
Journal of Biological ChemistryVol. 298Issue 12102679Published online: November 9, 2022- Ashley A. DaDalt
- Christopher A. Bonham
- Griffin P. Lotze
- Adrian A. Luiso
- Panayiotis O. Vacratsis
Cited in Scopus: 0Yeast VH1-related phosphatase (YVH1) (also known as DUSP12) is a member of the atypical dual-specificity phosphatase subfamily. Although no direct substrate has been firmly established, human YVH1 (hYVH1) has been shown to protect cells from cellular stressors, regulate the cell cycle, disassemble stress granules, and act as a 60S ribosome biogenesis factor. Despite knowledge of hYVH1 function, further research is needed to uncover mechanisms of its regulation. In this study, we investigate cellular effects of a Src-mediated phosphorylation site at Tyr179 on hYVH1. - Research ArticleOpen Access
Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer
Journal of Biological ChemistryVol. 298Issue 11102550Published online: September 29, 2022- Ou Deng
- Sweta Dash
- Thales C. Nepomuceno
- Bin Fang
- Sang Y. Yun
- Eric A. Welsh
- and others
Cited in Scopus: 0BRCA1/2-deficient ovarian carcinoma (OC) has been shown to be particularly sensitive to poly (ADP-ribose) polymerase inhibitors (PARPis). Furthermore, BRCA1/2 mutation status is currently used as a predictive biomarker for PARPi therapy. Despite providing a major clinical benefit to the majority of patients, a significant proportion of BRCA1/2-deficient OC tumors do not respond to PARPis for reasons that are incompletely understood. Using an integrated chemical, phospho- and ADP-ribosylation proteomics approach, we sought here to develop additional mechanism-based biomarker candidates for PARPi therapy in OC and identify new targets for combination therapy to overcome primary resistance.